Zhao et al. identified 44 active ingredients, after comparing the potential targets of XBJ with COVID-19 targets, and they suggested 44 treatment targets such as AKT1, TP53, TNF, JUN, EGFR, IL-1β, IL-10, and EGF. This evidence concerns the gene AKT1 and COVID-19.